The IMpassion132 phase III trial, published in July 2024, explored the impact of atezolizumab combined with chemotherapy for patients with rapidly relapsing, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The study focused on patients whose disease relapsed within 12 months of prior chemotherapy or surgery for early TNBC, a group facing significant treatment challenges.
The trial found that adding atezolizumab did not improve overall survival (OS) compared to chemotherapy alone, with median survival of 12.1 months versus 11.2 months, respectively. Progression-free survival (PFS) was 4 months across treatment arms, while the objective response rate (ORR) was 40% with atezolizumab versus 28% with chemotherapy alone. Despite atezolizumab’s manageable safety profile, these findings emphasize the need for new therapeutic strategies and a deeper understanding of resistance mechanisms to immunotherapy in TNBC.
We recognize Dr. Rebecca Dent for her leadership in this study, along with her dedicated team, whose efforts have contributed to advancing research in triple-negative breast cancer. Their commitment continues to shape the future of treatment in this challenging disease setting.
Read the full study here: https://lnkd.in/emvnV2sX
